Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4(+) T cells in MDS.
- DOI
- 10.1016/j.bneo.2025.100106
- Published
- 2025 Aug
- Container
- Blood neoplasia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bneo.2025.100106,
title = {Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4(+) T cells in MDS.},
author = {Griffiths EA and Srivastava P and Gomez EC and Matsuzaki J and Odunsi K and Dillon LW and Mukherjee D and Hourigan CS and Peng J and Bandyopadhyay S and Tan K and Attwood KM and Kuechle JB and Singh PK and Wang J and Nemeth MJ},
year = {2025},
journal = {Blood neoplasia},
doi = {10.1016/j.bneo.2025.100106},
url = {https://doi.org/10.1016/j.bneo.2025.100106}
}RIS
TY - JOUR TI - Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4(+) T cells in MDS. AU - Griffiths EA AU - Srivastava P AU - Gomez EC AU - Matsuzaki J AU - Odunsi K AU - Dillon LW AU - Mukherjee D AU - Hourigan CS AU - Peng J AU - Bandyopadhyay S AU - Tan K AU - Attwood KM AU - Kuechle JB AU - Singh PK AU - Wang J AU - Nemeth MJ PY - 2025 JO - Blood neoplasia DO - 10.1016/j.bneo.2025.100106 UR - https://doi.org/10.1016/j.bneo.2025.100106 ER -
APA
EA, G., P, S., EC, G., J, M., K, O., LW, D., D, M., CS, H., J, P., S, B., K, T., KM, A., JB, K., PK, S., J, W., & MJ, N. (2025). Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4(+) T cells in MDS.. Blood neoplasia. https://doi.org/10.1016/j.bneo.2025.100106
Source records
- pubmed · retrieved 2026-09-26T04:23:12.934Z